Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8332542 | 1.00 | FKBP1A (0.51) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL17893034 | 1.00 | FKBP1A (0.51) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL17153137 | 0.89 | PARP1 (0.53) | FKBP1AKLK7CTSLPARP1PDK1 | |
| SCHEMBL1448453 | 0.89 | POLB (0.53) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL1783541 | 0.89 | POLB (0.53) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL5499620 | 0.89 | KLK7 (0.47) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL13967419 | 0.89 | FKBP1A (0.47) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL21285649 | 0.89 | FKBP1A (0.47) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL21441908 | 0.89 | FKBP1A (0.47) | FKBP1AKLK7CTSLPARP1HPGD | |
| SCHEMBL1449334 | 0.89 | POLB (0.53) | FKBP1AKLK7CTSLPARP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240413-B1 | PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10433555-B2 | Picolinamide compounds with fungicidal activity | DOW AGROSCIENCES LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180000085-A1 | USE OF PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | CORTEVA AGRISCIENCE LLC | 2018-01-04 | — | — | US | disclosed |
| EP-3240412-A1 | USE OF PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | Dow Agrosciences LLC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240413-A1 | PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | Dow Agrosciences LLC (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109289-A1 | PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109288-A1 | USE OF PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10433555-B2 | Picolinamide compounds with fungicidal activity | PFAS, CASP2, CYP1A2 | FKBP1A 7/4885KLK7 3557/4885CTSL 619/4885 |
| US-20180000085-A1 | USE OF PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY | PFAS, CYP1A2, CYP51A1 | FKBP1A 7/4885KLK7 3243/4885CTSL 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.